Core Insights - Telix Pharmaceuticals reported a strong third-quarter performance for fiscal 2025, with revenues of $206 million, reflecting a 53% year-over-year increase and a 1% sequential increase [1] - The company has raised its fiscal year 2025 sales guidance from a range of $770 million-$800 million to $800 million-$820 million [6] Revenue Breakdown - PSMA imaging revenue increased by 17% to $155 million, while RLS third-party revenue reached $47 million [1] - The increase in dose volumes by 3% indicates that competitive pricing pressures are stabilizing [5] Product Developments - Gozellix, a radioactive diagnostic agent for prostate cancer, is now fully reimbursed by CMS, effective October 1 [2] - Illuccix has been approved in 19 European markets and the U.K., with commercial launches already initiated in several countries including the U.K., Germany, and France [3] Clinical Trials - The BiPASS trial for MRI + PSMA-PET for prostate cancer diagnosis has begun dosing its first patients [4] - The ProstACT Global Phase 3 trial–Part 2 is now open for enrollment, with preliminary safety profile and dosimetry results expected after patient monitoring [4] Market Performance - Telix Pharmaceuticals' stock increased by 3.60%, reaching $9.88 at the time of publication [6]
Telix Pharmaceuticals Enters Q4 On Strong Footing With Stabilized Pricing Pressures, Upgraded Annual Sales Guidance